4.7 Article

Excess mortality, length of stay and cost attributable to candidaemia

Journal

JOURNAL OF INFECTION
Volume 59, Issue 5, Pages 360-365

Publisher

W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2009.08.020

Keywords

Candida; Mortality; ICU

Funding

  1. Astellas Pharma Ltd, UK.

Ask authors/readers for more resources

Background: There were 1967 reports of Candida species isolated from blood specimens in 2007 in the UK (excluding Scotland). Such infections are particularly common in the intensive care unit (ICU). The impact of candidaemia on mortality, length of stay (LOS) and cost in a UK hospital was examined. Methods: A retrospective analysis of candidaemia episodes and appropriate matched controls was undertaken based on data from the ICU, high dependency units and hospital wards at Wythenshawe Hospital in Manchester. The study covered the period November 2003-February 2007. Results: In total, 48 case-patients of candidaemia and 81 control-patients were identified. The attributable mortality due to candidaemia varied from 21.5% to 34.7%. Candidaemia patients spend on average 5.6 days more in the ICU than matched patients and generate mean additional costs of at least 8252 pound per patient, 16,595 pound in adults only. Conclusion: Candidaemia remains a severe disease associated with high attributable mortality in the UK. In addition, candidaemia leads to additional ICU length of stay and costs. The implication is an attributable cost of at least 16.2 pound million with 683 deaths attributable to candidaemia per year in the UK. (c) 2009 The British Infection Society. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available